Deucravacitinib in dermatology: current indication and existing off-label data

Tyrosine kinase 2 (TYK2) inhibition has recently emerged as a novel therapeutic strategy in dermatology, targeting key cytokine pathways involved in immune-mediated inflammatory diseases. Deucravacitinib, an oral, selective TYK2 inhibitor that binds the regulatory pseudokinase domain, modulates sign...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Michela D’Agostino, Luca Potestio, Nello Tommasino, Matteo Megna
Format:	Artigo
Jezik:	Inglês
Izdano:	BioExcel Publishing Ltd 2026-06-01
Serija:	Drugs in Context
Teme:	dermatology deucravacitinib immunemediated inflammatory diseases psoriasis real-world evidence tyk2 inhibition
Online dostop:	https://www.drugsincontext.com/deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data/
Oznake:	Označite Brez oznak, prvi označite!